Protagenic Therapeutics Enters Material Definitive Agreement
Ticker: PTIXW · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $1,200,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement
Related Tickers: PTIX
TL;DR
PTIX signed a big deal, details TBD.
AI Summary
Protagenic Therapeutics, Inc. announced on January 9, 2025, that it entered into a material definitive agreement. The filing does not provide specific details about the agreement or any associated dollar amounts.
Why It Matters
This filing indicates a significant new development for Protagenic Therapeutics, potentially impacting its business operations and future strategy.
Risk Assessment
Risk Level: medium — The lack of specific details in the 8-K filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — Filer
- January 9, 2025 (date) — Date of Earliest Event Reported
FAQ
What is the nature of the material definitive agreement Protagenic Therapeutics entered into?
The filing states that Protagenic Therapeutics, Inc. entered into a material definitive agreement on January 9, 2025, but does not specify the details of this agreement.
Are there any financial terms or dollar amounts associated with this agreement mentioned in the filing?
No, the provided text of the 8-K filing does not mention any specific dollar amounts or financial terms related to the material definitive agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 9, 2025.
What is the company's ticker symbol?
The company's ticker symbol is PTIX.
What state is Protagenic Therapeutics, Inc. incorporated in?
Protagenic Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 900 words · 4 min read · ~3 pages · Grade level 10.6 · Accepted 2025-01-10 06:04:59
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share, having an aggregate offering
- $1,200,000 — ng an aggregate offering price of up to $1,200,000 (the "ATM Offering"). The Company is
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex1-1.htm (EX-1.1) — 21KB
- ex5-1.htm (EX-5.1) — 17KB
- ex5-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-25-001516.txt ( ) — 317KB
- ptix-20250109.xsd (EX-101.SCH) — 4KB
- ptix-20250109_def.xml (EX-101.DEF) — 29KB
- ptix-20250109_lab.xml (EX-101.LAB) — 36KB
- ptix-20250109_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. PROTAGENIC THERAPEUTICS, INC. By: /s/ Alexander K. Arrow Name: Alexander K. Arrow Title: Chief Financial Officer Dated: January 9, 2025